Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of iptacopan in C3 glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
jRCT2041220097Recruiting
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in Complement 3 glomerulopathy (C3G) and Primary immune complex membranoproliferative glomerulonephritis (MPGN), sponsored by Novartis. Primary endpoint: Primary safety endpoints. Started Nov 2022; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on jRCT2041220097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220097.